Anteris Technologies Global CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Anteris Technologies Global Corp. reported increased losses in Q3 2025 as R&D expenses surged for its DurAVR THV System, while successfully raising $25.2 million post-period to fund ongoing operations and clinical trials.
NASDAQ
Anteris Technologies Global Corp. reports increased losses in Q2 2025 as it ramps up manufacturing and clinical infrastructure for the PARADIGM Trial.
NASDAQ
Anteris Technologies Global Corp. reports a net loss of $21.9 million for the first quarter of 2025, driven by increased R&D spending as it prepares for the PARADIGM Trial.